Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients

14. května 2026 aktualizováno: Xin Yu, Sir Run Run Shaw Hospital

Efficacy of Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients With Colorectal Cancer: A Multicenter Randomized Controlled Trial Study Protocol

The goal of this clinical trial is to clarify the efficacy and safety of transcutaneous electrical acustimulation (TEA) in elderly patients with colorectal cancer, and to evaluate its clinical value in promoting postoperative intestinal function recovery and reducing the incidence of intestinal complications. The main questions it aims to answer are:

Can TEA promote the recovery of intestinal function in elderly patients with colon cancer after surgery? What medical problems might occur to the participants when using TEA? The researchers will compare TEA with the control group (non-acupoint sham stimulation) to see if TEA is effective in promoting the recovery of intestinal function after surgery.

Participants will:

Starting from the first day after the surgery, they received TEA or sham stimulation twice a day for a total of 3 days.

Record the time of the first defecation, defecation, and eating. Record their symptoms and adverse events.

Přehled studie

Postavení

Zatím nenabíráme

Typ studie

Intervenční

Zápis (Odhadovaný)

190

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Zhejiang
      • Hangzhou, Zhejiang, Čína
        • Sir Run Run Shaw Hospital
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Age ≥ 65 years old.
  • Elective minimally invasive (laparoscopic or robotic) resection of colorectal cancer.
  • American Society of Anesthesiologists classification (ASA) 1-4.
  • Able to understand the research process and the use of various assessment scales, and able to communicate effectively with the researchers.
  • The patient voluntarily participates in this study and signs the informed consent form.

Exclusion Criteria:

  • Previous history of abdominal gastrointestinal surgery.
  • Planned for palliative or emergency surgery.
  • Planned for open abdominal surgery or creation of a new stoma.
  • Transfer to ICU.
  • Diagnosed with severe heart, liver, kidney or mental system diseases.
  • Patients with implanted cardiac pacemakers.
  • Patients currently using or having used in the past month glucagon-like peptide-1 (GLP-1) receptor agonists, dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
  • Planned to use epidural anesthesia or epidural analgesia.
  • Presence of local skin lesions, infection at the stimulation site, or obvious skin allergy or severe skin sensitivity to electrodes/adhesive materials.
  • Participated in other clinical studies within the past 3 months or received acupuncture treatment within the past month.
  • Other conditions that the investigator considers make the patient unsuitable for participation in this study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Prevence
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: TEA
The subjects in the TEA group were placed in the supine position and received transcutaneous electrical acupoint stimulation at the bilateral PC6 and bilateral ST36 . After confirming the location of the acupoints , special skin treatment was carried out. The stimulation parameters for PC6 were set as follows: 0.1 seconds of opening stimulation, 0.4 seconds of closing stimulation, pulse width of 0.5 ms, pulse frequency of 100 Hz, and amplitude ranging from 1 to 10 mA (based on the maximum level that the subject could tolerate). The stimulation parameters for ST36 were set as follows: 2 seconds of opening stimulation, 3 seconds of closing stimulation, pulse width of 0.5 ms, pulse frequency of 25 Hz, and amplitude ranging from 2 to 10 mA (based on the maximum level that the subject could tolerate).
Falešný srovnávač: sham-TEA
Sham-TEA was the same except that non-acupoints were used to replace ST36 and PC6. The sham-acupoint for PC6 was located at about 15-20 cm away from PC6 (up to the elbow and outside of the coastal margin of the forearm not on any meridian) and the sham-point for ST36 was located at 10-15 cm down from and to the lateral side of ST36 not on any meridian

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time to First Flatus
Časové okno: Assessed up to 10 days after surgery
Defined as the period from the end of the surgery to the time of first flatus (hours).
Assessed up to 10 days after surgery

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Prolonged post operative ileus (PPOI)
Časové okno: Assessed up to 72 hours after surgery
defined as no flatus for more than 72 hours
Assessed up to 72 hours after surgery
time to first defecation
Časové okno: Assessed up to 10 days after surgery
Defined as the period from the end of the surgery to the time of first defecation (hours).
Assessed up to 10 days after surgery
time to first water intake
Časové okno: Assessed up to 10 days after surgery
The time from the end of the surgery to the first water intake (hours)
Assessed up to 10 days after surgery
Time to tolerance of liquid diet
Časové okno: Assessed up to 10 days after surgery
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after the liquid diet. Record the time (in hours) from the end of the surgery to the first tolerance to the liquid diet.
Assessed up to 10 days after surgery
Time to tolerance of semi-liquid diet
Časové okno: Assessed up to 10 days after surgery
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after semi-liquid food. Record the time ( hours) from the end of the surgery to the first tolerance of semi-liquid food.
Assessed up to 10 days after surgery
Time to tolerance of solid food
Časové okno: Assessed up to 10 days after surgery
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after solid food. Record the time (hours) from the end of the surgery to the first tolerance of solid food.
Assessed up to 10 days after surgery
Time to first ambulation
Časové okno: Assessed up to 10 days after surgery
The time from the end of the surgery to the first ambulation (hours).
Assessed up to 10 days after surgery
Postoperative nausea
Časové okno: At 24, 48, and 72 hours after surgery
The number and frequency of postoperative nausea episodes
At 24, 48, and 72 hours after surgery
postoperative vomiting
Časové okno: At 24, 48, and 72 hours after surgery
The number and frequency of postoperative vomiting
At 24, 48, and 72 hours after surgery
postoperative abdominal distension
Časové okno: At 24, 48, and 72 hours after surgery
The number and frequency of postoperative abdominal distension
At 24, 48, and 72 hours after surgery
Use of anti-emetic drugs after surgery
Časové okno: At 24, 48, and 72 hours after surgery
Number of participants using antiemetic drugs
At 24, 48, and 72 hours after surgery
Severity of postoperative pain
Časové okno: At 24, 48, and 72 hours after surgery
The assessment was conducted using a numerical rating scale (NRS). The scoring range was 0-10 (0 indicated no pain, while 10 indicated unbearable severe pain. Scores of 1-3 indicated mild pain that could be tolerated; 4-6 indicated pain that affected sleep but was still tolerable; 7-10 indicated severe pain that affected appetite and sleep).
At 24, 48, and 72 hours after surgery
Use of opioids drugs after surgery
Časové okno: At 24, 48, and 72 hours after surgery
The total dosage of all opioid analgesics used within 24 hours, 48 hours, and 72 hours after surgery, converted into morphine equivalents.
At 24, 48, and 72 hours after surgery
TEA Security
Časové okno: Assessed up to 3 days after surgery
assessing the adverse events related to the equipment (including numbness in the hands, pain, and skin allergies)
Assessed up to 3 days after surgery
Postoperative complications
Časové okno: From the time the patient signs the informed consent form until the end of the study follow-up (30 days after surgery)
The severity of complications was evaluated using the Clavien-Dindo classification system (grades I to V), with Clavien-Dindo grade ≥ III complications serving as the major surgical complications.
From the time the patient signs the informed consent form until the end of the study follow-up (30 days after surgery)
Total length of hospital stay
Časové okno: Assessed up to 30 days after surgery
primary admission plus any readmission up to 30 days
Assessed up to 30 days after surgery
Unplanned readmission
Časové okno: Assessed up to 30 days after surgery
Record the number of unplanned re-admissions within 30 days of hospital discharge
Assessed up to 30 days after surgery
Postoperative quality of recovery
Časové okno: baseline and postoperative day 1 to day 7 (or until discharge, whichever comes first)
Assessed using the Quality of Recovery - 15 score (QoR-15) questionnaire preoperatively and daily. The total score ranges from 0 to 150 points. The higher the score, the better the post-anesthesia recovery quality.
baseline and postoperative day 1 to day 7 (or until discharge, whichever comes first)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. června 2026

Primární dokončení (Odhadovaný)

31. prosince 2028

Dokončení studie (Odhadovaný)

31. prosince 2028

Termíny zápisu do studia

První předloženo

30. dubna 2026

První předloženo, které splnilo kritéria kontroly kvality

30. dubna 2026

První zveřejněno (Aktuální)

8. května 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

15. května 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

14. května 2026

Naposledy ověřeno

1. května 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na TEA

Předplatit